US Food and Drug Administration officials are preparing for a potentially complicated assessment of the Pfizer Inc./BioNTech SE coronavirus vaccine in young children as pressure grows to find ways to better protect them during the Omicron surge.
The ongoing Comirnaty clinical trial did not meet its non-inferiority endpoint in the 2- to 5-year-old age group, but did...







